Many rheumatologic conditions such as rheumatoid arthritis and lupus often strike women during their reproductive years, with drugs being the primary therapies. Experts assembled by EULAR determined ...

Fate Therapeutics, Inc. (NASDAQ:FATE) is among the best get rich quick stocks to buy now. Analysts at H.C. Wainwright have reaffirmed their Neutral rating on Fate Therapeutics, Inc. (NASDAQ:FATE), ...

BARCELONA, Spain — Patients with rheumatoid arthritis (RA) who have not responded to first-line methotrexate therapy should be started on a biologic or targeted synthetic disease-modifying ...

BARCELONA, Spain--(BUSINESS WIRE)--Hospital for Special Surgery (HSS) presented a research study at the European Alliance of Associations for Rheumatology (EULAR) Annual Meeting showing that an ...

In 2023, EULAR welcomed Professor Daniel Aletaha to the role, but it is now time for him to hand the baton on to the next in line. We are delighted to have Xenofon Baraliakos as the new EULAR ...

Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company based in Ness-Ziona, Israel, announced it will present data on Allocetra™, its proprietary macrophage reprogramming cell therapy for ...

PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell ...

SINGAPORE and PRINCETON, N.J., May 19, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced that it will be presenting topline ...

Please provide your email address to receive an email when new articles are posted on . A new trial center network and two major data collection projects are among recent EULAR initiatives for ...

The European Alliance of Associations for Rheumatology (EULAR) 2024 European Congress of Rheumatology Annual Meeting is about to take place in Vienna, Austria. From June 12-15, some of the world's ...

New safety and efficacy data on the drug therapy, LUPKYNIS® (voclosporin), will be presented at the European Alliance of Associations Rheumatology (EULAR) Congress 2024 later this month. The data ...